Chroma Medicine, Inc.
1400 One Kendall Square
11 articles about Chroma Medicine, Inc.
Chroma Medicine Presents Preclinical In Vivo Data Showing Durable Cholesterol Reduction with a PCSK9-Targeted Epigenetic Editor at the 2023 AHA Scientific Sessions
Chroma Medicine, Inc. presented new preclinical data demonstrating that a single administration of its epigenetic editor efficiently and durably lowered PCSK9 and cholesterol levels in non-human primates in a late-breaking oral presentation at the 2023 American Heart Association Scientific Sessions, held November 11-13 in Philadelphia.
Chroma Medicine to Showcase Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual Meeting
Chroma Medicine, Inc. announced that it will present a poster demonstrating the potential of its multiplex epigenetic editing platform at the American Society of Hematology 65th Annual Meeting, taking place December 9-12, 2023, in San Diego, CA.
Chroma Medicine Strengthens Leadership with the Appointment of Biotech Business Leader Michael A. Kelly to its Board of Directors
Chroma Medicine, Inc. announced the addition of innovative biotech business leader Michael A. Kelly to its Board of Directors.
Chroma Medicine Presents Data Showing Specific and Durable HBV Silencing with Epigenetic Editors at the HBV International Meeting 2023
Chroma Medicine, Inc., a genomic medicine company pioneering single-dose epigenetic editing therapeutics, presented positive preclinical data demonstrating the potential of its epigenetic editors to produce efficacious, specific, and durable silencing of the hepatitis B virus during the HBV International Meeting 2023, held September 19-23 in Kobe, Japan.
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
Sangamo Therapeutics, Inc. today announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition.
Chroma Medicine Announces Data Demonstrating the Benefits of Epigenetic Editing for Multiplex Gene Regulation at ASGCT 2023
Chroma Medicine, Inc., a genomic medicine company pioneering single-dose epigenetic editing therapeutics, presented data demonstrating the advantages of epigenetic editing for multiplex gene regulation at the American Society of Gene & Cell Therapy 26th Annual Meeting in Los Angeles.
Chroma Medicine Presents Data Demonstrating Near-Complete, Durable In Vivo Silencing with Targeted Epigenetic Editors at 2023 ASGCT Annual Meeting
Chroma Medicine, Inc. announced in vivo data that demonstrate 99% silencing of two distinct targets and compelling proof-of-concept for its epigenetic editing platform.
Chroma Medicine to Present First Data Demonstrating Promise of Its Epigenetic Editing Platform at 26th ASGCT Annual Meeting
Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced two oral data presentations that showcase the potential of its epigenetic editing platform at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting.
Backed by Google Ventures, ARCH Venture Partners and more, Chroma Medicine announced the closing of a $135 million Series B financing Wednesday.
Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines
Chroma Medicine, Inc. announced the completion of a $135 million Series B financing led by GV, with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management.
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.